title: Teicoplanin use and emergence of Staphylococcus haemolyticus: is there a link?
authors.forename: M
authors.initials: M
authors.lastname: Falcone
authors.forename: M
authors.initials: M
authors.lastname: Giannella
authors.forename: G
authors.initials: G
authors.lastname: Raponi
authors.forename: C
authors.initials: C
authors.lastname: Mancini
authors.forename: M
authors.initials: M
authors.lastname: Venditti
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D024881:Drug Resistance, Bacterial; D006801:Humans; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D041162:Staphylococcus haemolyticus / Q000187:drug effects* / Q000302:isolation & purification; D017334:Teicoplanin / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D017334:Teicoplanin